Extended Follow-up of the International Randomized Phase 3 First-Line Indolent Trial (FIT) Shows Durable Benefit of Y-90-Ibritumomab Tiuxetan (Zevalin (R)) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin's Lymphoma

Franck Morschhauser; Angelika Bischof-Delaloye; Ama Z. S. Rohatiner; Gilles Andre Salles; Jens Kuhlmann; Willem J. L. Van Putten; John Radford; Pierre Soubeyran; Achiel Van Hoof; Anton Hagenbeek

Extended Follow-up of the International Randomized Phase 3 First-Line Indolent Trial (FIT) Shows Durable Benefit of Y-90-Ibritumomab Tiuxetan (Zevalin (R)) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin's Lymphoma

Franck Morschhauser, Angelika Bischof-Delaloye, Ama Z. S. Rohatiner, Gilles Andre Salles, Jens Kuhlmann, Willem J. L. Van Putten, John Radford, Pierre Soubeyran, Achiel Van Hoof, Anton Hagenbeek

Research output: Contribution to journal › Article › peer-review

Original language	Undefined
Pages (from-to)	698-698
Number of pages	1
Journal	Blood
Volume	112
Issue number	11
Publication status	Published - 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Morschhauser, F., Bischof-Delaloye, A., Rohatiner, A. Z. S., Salles, G. A., Kuhlmann, J., Van Putten, W. J. L., Radford, J., Soubeyran, P., Van Hoof, A., & Hagenbeek, A. (2008). Extended Follow-up of the International Randomized Phase 3 First-Line Indolent Trial (FIT) Shows Durable Benefit of Y-90-Ibritumomab Tiuxetan (Zevalin (R)) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin's Lymphoma. Blood, 112(11), 698-698.

Morschhauser, Franck ; Bischof-Delaloye, Angelika ; Rohatiner, Ama Z. S. et al. / Extended Follow-up of the International Randomized Phase 3 First-Line Indolent Trial (FIT) Shows Durable Benefit of Y-90-Ibritumomab Tiuxetan (Zevalin (R)) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin's Lymphoma. In: Blood. 2008 ; Vol. 112, No. 11. pp. 698-698.

@article{fab403004ebf40018e760c7b6139fcf3,

title = "Extended Follow-up of the International Randomized Phase 3 First-Line Indolent Trial (FIT) Shows Durable Benefit of Y-90-Ibritumomab Tiuxetan (Zevalin (R)) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin's Lymphoma",

author = "Franck Morschhauser and Angelika Bischof-Delaloye and Rohatiner, {Ama Z. S.} and Salles, {Gilles Andre} and Jens Kuhlmann and {Van Putten}, {Willem J. L.} and John Radford and Pierre Soubeyran and {Van Hoof}, Achiel and Anton Hagenbeek",

year = "2008",

language = "Undefined",

volume = "112",

pages = "698--698",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "11",

}

Morschhauser, F, Bischof-Delaloye, A, Rohatiner, AZS, Salles, GA, Kuhlmann, J, Van Putten, WJL, Radford, J, Soubeyran, P, Van Hoof, A & Hagenbeek, A 2008, 'Extended Follow-up of the International Randomized Phase 3 First-Line Indolent Trial (FIT) Shows Durable Benefit of Y-90-Ibritumomab Tiuxetan (Zevalin (R)) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin's Lymphoma', Blood, vol. 112, no. 11, pp. 698-698.

Extended Follow-up of the International Randomized Phase 3 First-Line Indolent Trial (FIT) Shows Durable Benefit of Y-90-Ibritumomab Tiuxetan (Zevalin (R)) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin's Lymphoma. / Morschhauser, Franck; Bischof-Delaloye, Angelika; Rohatiner, Ama Z. S. et al.
In: Blood, Vol. 112, No. 11, 2008, p. 698-698.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Extended Follow-up of the International Randomized Phase 3 First-Line Indolent Trial (FIT) Shows Durable Benefit of Y-90-Ibritumomab Tiuxetan (Zevalin (R)) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin's Lymphoma

AU - Morschhauser, Franck

AU - Bischof-Delaloye, Angelika

AU - Rohatiner, Ama Z. S.

AU - Salles, Gilles Andre

AU - Kuhlmann, Jens

AU - Van Putten, Willem J. L.

AU - Radford, John

AU - Soubeyran, Pierre

AU - Van Hoof, Achiel

AU - Hagenbeek, Anton

PY - 2008

Y1 - 2008

UR - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000262104702335&KeyUID=WOS:000262104702335

M3 - Article

SN - 0006-4971

VL - 112

SP - 698

EP - 698

JO - Blood

JF - Blood

IS - 11

ER -

Extended Follow-up of the International Randomized Phase 3 First-Line Indolent Trial (FIT) Shows Durable Benefit of Y-90-Ibritumomab Tiuxetan (Zevalin (R)) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin's Lymphoma

UN SDGs

Other files and links

Cite this